NCT04569591View on ClinicalTrials.gov

Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease

NANot yet recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Cushing's DiseasePituitary Adenoma
Interventions
DRUG

Acthrel

Intravenous administration of ovine CRH (Acthrel (Registered Trademark) 1 mcg/kg up to a maximum dose of 100 mcg) results in selective increase in ACTH activity of pituitary adenomas within two minutes and peaks between 10-15 minutes.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT04569591 - Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease | Biotech Hunter | Biotech Hunter